Want to see CMPS full AI Analyst Report?
Top Page
COMPASS Pathways
(NASDAQ:CMPS)
Select Model
Select Model
Rating:56Neutral
Price Target:
$12.00
▲(6.57% Upside)
Action:Reiterated
Date:08/05/26
CMPS scores modestly positive overall, driven primarily by a strong earnings-call outlook (Phase III strength, active rolling NDA, and well-funded path to potential H1 2027 launch). This is tempered by weak financial performance typical of pre-revenue biotech (large and expanding losses and cash burn), with mixed technical signals and limited support from traditional valuation metrics due to negative earnings and no dividend.
Positive Factors
Clinical Efficacy (Phase III)
Two independent Phase III readouts showing statistically significant primary endpoint results, rapid onset (as early as Day 1) and maintained benefit through six months materially reduce clinical risk. Durable efficacy strengthens the regulatory case, supports prescriber confidence and underpins longer-term commercial potential.
Negative Factors
Pre-revenue with Growing Losses
The company remains pre-revenue while R&D and operating spend have accelerated, producing very large trailing losses and persistent negative operating cash flow. This structural cash burn means long-term viability depends on successful approval and commercialization, leaving funding and execution risk until revenues materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Efficacy (Phase III)
Two independent Phase III readouts showing statistically significant primary endpoint results, rapid onset (as early as Day 1) and maintained benefit through six months materially reduce clinical risk. Durable efficacy strengthens the regulatory case, supports prescriber confidence and underpins longer-term commercial potential.
Read all positive factors
COMPASS Pathways (CMPS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.53B
Dividend YieldN/A
Average Volume (3M)4.09M
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue GrowthN/A
EPS Growth-9.94%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.62
Shares Outstanding134,949,330
10 Day Avg. Volume4,389,808
30 Day Avg. Volume4,091,092
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.14Price Target Upside114.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$2.00M
COMPASS Pathways Business Overview & Revenue Model
Company Description
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP3...
How the Company Makes Money
null...
COMPASS Pathways Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and commercial momentum: highly statistically significant Phase III efficacy, demonstrated 6-month durability, a generally favorable safety profile, an active rolling NDA with modules under review, a healthy cash position ($433M) through 2028, extensive commercial hiring, strong prescriber interest (~90% willing to prescribe), and substantial launch planning (training, payer engagement, partnerships). Key risks highlighted are timing and sequencing uncertainties around DEA rescheduling and REMS finalization, ongoing payer negotiations, remaining 52-week safety data submission, and potential competitive entrants. On balance, the positive clinical results and robust launch preparedness materially outweigh the timing and regulatory uncertainties.Positive Updates
Statistically Significant Phase III Results
COMPASS reported highly statistically significant positive primary endpoint readouts from two Phase III trials for COMP360, with demonstrated rapid onset (as quickly as 1 day) and durability sustained through at least 6 months.
Negative Updates
Regulatory Timing and Guidance Uncertainties
New FDA guidance referencing 12-month blinded durability was noted as a tall order for psychiatry drugs; while COMPASS does not expect current guidance to derail the ongoing review, it creates regulatory uncertainty for future programs.
Read all updates
Q2-2026 Updates
Positive
Negative
Statistically Significant Phase III Results
COMPASS reported highly statistically significant positive primary endpoint readouts from two Phase III trials for COMP360, with demonstrated rapid onset (as quickly as 1 day) and durability sustained through at least 6 months.
Read all positive updates
Company Guidance
The call guided that COMPASS is advancing a rolling NDA submission (some modules already under review) with completion expected in Q4 2026 and potential for accelerated approval, targeting a commercial launch in H1 2027; key program metrics highlighted included two Phase III trials with highly statistically significant positive primary endpoints, rapid onset of effect as early as Day 1, durability through at least 6 months (with both studies providing 26‑week data and full safety follow‑up to 52 weeks), a 300‑patient PTSD study (3 arms, VA/military‑related patients capped at ≤15%), a post‑hoc finding that ~80% of administration sessions were silent, and commercial/readiness metrics including $433M cash on hand as of June 30, 2026 (runway into 2028), ~8,000 existing interventional psychiatry sites (growing ~500 sites/quarter), ~90% of interventional psychiatrists saying they would prescribe within the first year, >1,000 people already trained on the psychedelic portion of site training, 8 strategic collaborations, sales force recruiting underway, commercial leadership whose direct reports have led >70 product launches, an anticipated REMS minimum monitoring time of 6 hours, and the expectation that DEA rescheduling typically follows a ~90‑day process.COMPASS Pathways Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -192.02M | -285.60M | -148.82M | -115.24M | -90.77M | -71.37M |
| Net Income | -394.19M | -287.86M | -155.12M | -118.46M | -91.50M | -71.74M |
Balance Sheet | ||||||
| Total Assets | 504.56M | 210.35M | 213.67M | 275.99M | 197.29M | 300.90M |
| Cash, Cash Equivalents and Short-Term Investments | 433.30M | 149.61M | 165.08M | 220.20M | 143.21M | 273.24M |
| Total Debt | 3.90M | 20.93M | 32.19M | 33.05M | 1.93M | 3.61M |
| Total Liabilities | 420.03M | 263.20M | 58.97M | 50.24M | 16.01M | 16.49M |
| Stockholders Equity | 84.53M | -52.85M | 154.69M | 225.74M | 181.28M | 284.41M |
Cash Flow | ||||||
| Free Cash Flow | -161.14M | -157.24M | -119.19M | -97.44M | -106.05M | -68.08M |
| Operating Cash Flow | -161.14M | -157.24M | -119.19M | -97.38M | -105.45M | -67.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -64.00K | -596.00K | -334.00K |
| Financing Cash Flow | 370.20M | 140.71M | 63.82M | 173.83M | 1.04M | 156.65M |
COMPASS Pathways Technical Analysis
Positive
11.26
Price Trends
12.47
Negative
10.06
Positive
8.28
Positive
Market Momentum
-0.36
Positive
47.86
Neutral
58.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPS, the sentiment is Positive. The current price of 11.26 is below the 20-day moving average (MA) of 12.18, below the 50-day MA of 12.47, and above the 200-day MA of 8.28, indicating a neutral trend. The MACD of -0.36 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMPS.
COMPASS Pathways Risk Analysis
COMPASS Pathways disclosed 100 risk factors in its most recent earnings report. COMPASS Pathways reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
COMPASS Pathways Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $874.42M | 1,110.64 | 1.03% | ― | 22.64% | -58.05% | |
60 Neutral | $428.06M | -4.34 | -27.10% | ― | -20.37% | -479.68% | |
60 Neutral | $1.53B | -4.04 | -146.01% | ― | -2.82% | -45.70% | |
59 Neutral | $1.54B | -37.65 | -9.20% | ― | 14.13% | 62.92% | |
56 Neutral | $1.53B | -5.28 | -150.89% | ― | ― | -9.94% | |
53 Neutral | $485.92M | -13.89 | 326.77% | ― | 35.37% | 46.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CMPS
COMPASS Pathways
11.80
7.44
170.64%
CCRN
Cross Country Healthcare
13.25
0.15
1.15%
TOI
Oncology Institute
5.17
1.10
27.03%
TALK
Talkspace
5.15
2.74
113.69%
INNV
InnovAge Holding
10.85
7.47
221.01%
AGL
Agilon Health
94.78
72.53
325.98%
COMPASS Pathways Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Compass Pathways reports positive Phase 3 depression results
Positive
Jul 7, 2026
On July 7, 2026, Compass Pathways reported 26-week results from Part B of its second Phase 3 COMP006 trial of COMP360 psilocybin in treatment-resistant depression, involving nearly 600 patients with highly chronic illness. The data confirmed rapid...
Executive/Board ChangesDividendsFinancial DisclosuresShareholder Meetings
COMPASS Pathways Shareholders Approve 2026 AGM Proposals, Board Changes
Positive
May 28, 2026
COMPASS Pathways held its 2026 Annual General Meeting of Shareholders on May 27, 2026, with 58,880,058 ordinary shares represented in person or by proxy and ADSs without voting instructions classified as broker non-votes. Shareholders re-elected d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.